European Commission Approves GSK/Pfizer-Backed HIV Infection Prevention Drug
Portfolio Pulse from Vandana Singh
The European Commission has approved ViiV Healthcare's Apretude, a drug for HIV prevention. ViiV Healthcare is majority owned by GSK plc, with Pfizer Inc and Shionogi as shareholders. The drug reduces the number of doses needed for effective HIV prevention from 365 daily pills to as few as six injections per year. It has demonstrated superior efficacy to daily oral emtricitabine/tenofovir disoproxil fumarate in reducing the risk of HIV acquisition in clinical trials.
September 19, 2023 | 1:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GSK, the majority owner of ViiV Healthcare, has received approval for its HIV prevention drug Apretude by the European Commission. This could potentially boost GSK's revenues in the future.
The approval of Apretude by the European Commission opens up a new market for GSK. This could potentially increase the company's revenues, which would likely have a positive impact on its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Pfizer, a shareholder in ViiV Healthcare, could potentially benefit from the approval of the HIV prevention drug Apretude by the European Commission.
As a shareholder in ViiV Healthcare, Pfizer stands to benefit from the approval of Apretude. This could potentially increase Pfizer's revenues and have a positive impact on its stock price in the short term.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 60